| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis
|
Hauser, Anthony
|
|
|
148 |
C |
p. 135-145
|
article
|
| 2 |
A general explanation of the counterfactual definition of confounding
|
Suzuki, Etsuji
|
|
|
148 |
C |
p. 189-192
|
article
|
| 3 |
A multistakeholder development process to prioritize and translate COVID-19 health recommendations for patients, caregivers and the public. A case study of the COVID-19 recommendation map
|
Pottie, Kevin
|
|
|
148 |
C |
p. 104-114
|
article
|
| 4 |
A novel methodological framework was described for detecting and quantifying overdiagnosis
|
Bell, Katy
|
|
|
148 |
C |
p. 146-159
|
article
|
| 5 |
Artificial intelligence in COVID-19 evidence syntheses was underutilized, but impactful: a methodological study
|
Tercero-Hidalgo, Juan R.
|
|
|
148 |
C |
p. 124-134
|
article
|
| 6 |
Assessing long-term effects after stem cell transplantation: design of the MOSA study
|
Wauben, Bianca
|
|
|
148 |
C |
p. 10-16
|
article
|
| 7 |
Causal language use in systematic reviews of observational studies is often inconsistent with intent: a systematic survey
|
Han, Mi Ah
|
|
|
148 |
C |
p. 65-73
|
article
|
| 8 |
Comparative effectiveness research considered methodological insights from simulation studies in physician's prescribing preference
|
Zhang, Lisong
|
|
|
148 |
C |
p. 74-80
|
article
|
| 9 |
Confounders and co-interventions identified in non-randomized studies of interventions
|
Pufulete, Maria
|
|
|
148 |
C |
p. 115-123
|
article
|
| 10 |
Coronavirus disease 2019 scenarios for a long-term strategy under fundamental uncertainty
|
Brom, Frans
|
|
|
148 |
C |
p. 196-199
|
article
|
| 11 |
Editorial Board
|
|
|
|
148 |
C |
p. IFC
|
article
|
| 12 |
Editors’ Choice: August 2022
|
Tovey, David
|
|
|
148 |
C |
p. A1-A2
|
article
|
| 13 |
Empirical studies of balance do not justify a requirement for 1,000 patients per trial
|
Senn, Stephen
|
|
|
148 |
C |
p. 184-188
|
article
|
| 14 |
Five common pitfalls in mixed methods systematic reviews: lessons learned
|
Lizarondo, Lucylynn
|
|
|
148 |
C |
p. 178-183
|
article
|
| 15 |
Geriatric impairments were directly and indirectly associated with mortality in older patients with cancer: a structural equation analysis
|
Canouï-Poitrine, Florence
|
|
|
148 |
C |
p. 17-26
|
article
|
| 16 |
High-cited favorable studies for COVID-19 treatments ineffective in large trials
|
Ioannidis, John P.A.
|
|
|
148 |
C |
p. 1-9
|
article
|
| 17 |
Improved adjusted minimal important change took reliability of transition ratings into account
|
Terluin, Berend
|
|
|
148 |
C |
p. 48-53
|
article
|
| 18 |
Indirectness (transferability) is critical when considering existing economic evaluations for GRADE clinical practice guidelines: a systematic review
|
Riva, John J.
|
|
|
148 |
C |
p. 81-92
|
article
|
| 19 |
Missing data were poorly reported and handled in randomized controlled trials with repeatedly measured continuous outcomes: a cross-sectional survey
|
Ren, Yan
|
|
|
148 |
C |
p. 27-38
|
article
|
| 20 |
Most healthcare interventions tested in Cochrane Reviews are not effective according to high quality evidence: a systematic review and meta-analysis
|
Howick, Jeremy
|
|
|
148 |
C |
p. 160-169
|
article
|
| 21 |
Most patients reported positively or neutrally of having served as controls in the trials within cohorts design
|
Verweij, Maaike E.
|
|
|
148 |
C |
p. 39-47
|
article
|
| 22 |
Recruitment and implementation challenges were common in stepped-wedge cluster randomized trials: Results from a methodological review
|
Caille, Agnes
|
|
|
148 |
C |
p. 93-103
|
article
|
| 23 |
Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry
|
Neven, Anouk
|
|
|
148 |
C |
p. 54-64
|
article
|
| 24 |
RETRACTED: Part II: a step-by-step guide to latent class analysis
|
Aflaki, Kayvan
|
|
|
148 |
C |
p. 170-173
|
article
|
| 25 |
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias
|
Ribeiro, Tatiane Bomfim
|
|
|
148 |
C |
p. 193-195
|
article
|
| 26 |
Table of Contents
|
|
|
|
148 |
C |
p. ii-iv
|
article
|
| 27 |
The Charlson Comorbidity Index: problems with use in epidemiological research
|
Drosdowsky, Allison
|
|
|
148 |
C |
p. 174-177
|
article
|
Journal description